FIELD: medicine.
SUBSTANCE: chimeric peptide VP-22_p16INK4a contains two sequences of amino acids one of which comprises a cycline kinase inhibitor in the form of an active fragment of p16INK4a as a therapeutic agent, while another one comprises the peptide VP22 of herpex simplex virus as a transport agent for transporting the cycline kinase inhibitor inside the target cells.
EFFECT: invention enables extending the range of application of said chimeric peptide.
4 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC PEPTIDE FOR EPITHELIAL AND MESENCHYMAL MALIGNANT NEOPLASMS TREATMENT | 2008 |
|
RU2369402C1 |
| CHIMERIC PEPTIDE AND PHARMACEUTICAL COMPOSITION FOR TREATING CANCER | 2010 |
|
RU2435783C1 |
| CHIMERIC PROTEIN FOR MALIGNANT LYMPHOMA TREATMENT | 2004 |
|
RU2297241C2 |
| POLYPEPTIDES FOR TREATING ONCOLOGICAL DISEASES | 2017 |
|
RU2728870C2 |
| MONOMOLECULAR CHIMERIC T-CELL RECEPTOR TO CANCER ANTIGEN CA125 | 2018 |
|
RU2747095C2 |
| SINGLE-CHAIN ANTIBODY TO CARCINOEMBRYONIC ANTIGEN, CHIMERIC MONOMOLECULAR T-CELL RECEPTOR, VECTOR AND HOST CELL FOR PROVISION OF SUCH RECEPTOR AND METHOD OF DIAGNOSTICS OR TREATMENT | 2012 |
|
RU2522004C2 |
| MONOMOLECULAR CHEMERIC T-CELLULAR RECEPTOR TO CANCER-EMBRYONIC ANTIGEN | 2015 |
|
RU2650858C2 |
| MONOMOLECULAR CHIMERIC T-CELLULAR RECEPTOR TO CANCER-EMBRYONIC ANTIGEN | 2015 |
|
RU2652955C1 |
| METHOD FOR NEOPLASTIC DISEASE DETECTION ON THE BASIS OF SOLUBILISED PHYSIOLOGICAL SAMPLE | 2004 |
|
RU2405158C2 |
| METHOD OF REDUCING THE NUMBER OF STEM CELLS OF HUMAN BREAST ADENOCARCINOMA | 2022 |
|
RU2798550C2 |
